3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
13
Breast Neoplasms
11
Carcinoma, Transitional Cell
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
3
Small Cell Lung Carcinoma
2
Urothelial Bladder Carcinoma
1
Salivary Gland Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Liver Failure
1
HRD Cancer
1
Glioblastoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma, Small Cell
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
pembrolizumab
38
Bevacizumab
25
Cyclophosphamide
23
Blood Specimen Collection
19
Standard of Care
17
Nivolumab
17
Carboplatin
16
Exercise
15
Paclitaxel
14
atezolizumab
13
Gemcitabine
13
Pemetrexed
12
Cisplatin
12
Fluorouracil
11
Doxorubicin
11
Radiotherapy
10
Cetuximab
10
Rituximab
9
Oxaliplatin
9
Magnetic Resonance Spectroscopy
9
Leucovorin
9
Docetaxel
9
Biopsy
9
130-nm albumin-bound paclitaxel
9
durvalumab
8
abemaciclib
8
Temozolomide
8
Surveys and Questionnaires
8
Prednisone
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms
×
sacituzumab govitecan
×
90 days
×
Clear all
No trials found.